Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company

Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply

Fineline Cube Apr 11, 2024

Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals...

Company Deals

Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation

Fineline Cube Apr 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...

Company Deals

Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China

Fineline Cube Apr 11, 2024

Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors

Fineline Cube Apr 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...

Company

Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...

Company Deals

Merck Sharp & Dohme Acquires Abceutics for Next-Generation ADC Technology

Fineline Cube Apr 10, 2024

Global healthcare leader Merck, Sharp & Dohme (MSD) (NYSE: MRK) has secured a strategic acquisition...

Company Deals

Bayer Partners with Google Cloud to Develop AI-Powered Medical Imaging Solutions

Fineline Cube Apr 10, 2024

Germany’s pharmaceutical and life sciences giant Bayer (ETR: BAYN) has joined forces with US technology...

Company Drug

Simcere Pharmaceutical’s SIM0500 Earns FDA Fast-Track Designation for Multiple Myeloma

Fineline Cube Apr 10, 2024

Simcere Pharmaceutical Group (HKG: 2096), a leading China-based pharmaceutical company, has announced that its trispecific...

Company Drug

Roche’s Inavolisib Earns Priority Review Status in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has received priority review status from China’s Center for...

Company Drug

Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer

Fineline Cube Apr 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Pipeline with NMPA Approvals for Three Drugs

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National...

Company Deals

Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development

Fineline Cube Apr 10, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has...

Company Deals

Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline

Fineline Cube Apr 10, 2024

Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the...

Company Deals

Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China

Fineline Cube Apr 10, 2024

US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for HRS-4642 Clinical Trial in KRAS G12D Mutated Tumors

Fineline Cube Apr 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

Alphamab Oncology’s JSKN003 Demonstrates Promising Results in Phase I HER2-Targeted Solid Tumor Study

Fineline Cube Apr 10, 2024

Alphamab Oncology (HKG: 9966) presented compelling data from a Phase I clinical trial of its...

Company Drug

Gan & Lee Pharmaceuticals Commences Clinical Trial for Innovative GLP-1 Agonist GZR18

Fineline Cube Apr 9, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading Chinese pharmaceutical company, has announced the commencement...

Company

BeiGene Launches Guangzhou ADC Production Park to Strengthen Manufacturing Muscle

Fineline Cube Apr 9, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company, has announced the operational...

Drug R&D

Shanghai’s 9th People’s Hospital Launches Groundbreaking Gene Therapy Trial for Congenital Deafness

Fineline Cube Apr 9, 2024

In a medical first, Shanghai’s 9th People’s Hospital has initiated the world’s inaugural clinical trial...

Policy / Regulatory

Shanghai Health Commission Implements Strict Guidelines to Curb Medical Sector Misconduct

Fineline Cube Apr 9, 2024

The Shanghai Municipal Health Commission has issued the “Implementation Rules for the Nine Guidelines for...

Posts pagination

1 … 341 342 343 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.